Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round
Biotech entrepreneur Michael Gilman is now on to his fourth startup Suzanne Kreiter, Boston Globe
Over the past couple of years, the pioneers in the CAR-T field have made some phenomenal leaps forward, and been hit with some of the most dramatic setbacks in biotech. They’ve offered advanced stage cancer patients a second lease on life, and run into daunting hurdles on the outer limits marked by the graves of patients. And now a biotech upstart is graduating from a substantial — and very quiet — seed effort in a drive to the clinic with a new tech specifically designed to address the biggest challenges in CAR-T.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.